Intra-operatively customized implant coating strategies for local and controlled drug delivery to bone.

Bone is one of the few tissues in the human body with high endogenous healing capacity. However, failure of the healing process presents a significant clinical challenge; it is a tremendous burden for the individual and has related health and economic consequences. To overcome such healing deficits, various concepts for a local drug delivery to bone have been developed during the last decades. However, in many cases these concepts do not meet the specific requirements of either surgeons who must use these strategies or individual patients who might benefit from them. We describe currently available methods for local drug delivery and their limitations in therapy. Various solutions for drug delivery to bone focusing on clinical applications and intra-operative constraints are discussed and drug delivery by implant coating is highlighted. Finally, a new set of design and performance requirements for intra-operatively customized implant coatings for controlled drug delivery is proposed. In the future, these requirements may improve approaches for local and intra-operative treatment of patients.

[1]  Qixin Zheng,et al.  Porous nano-HA/collagen/PLLA scaffold containing chitosan microspheres for controlled delivery of synthetic peptide derived from BMP-2. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[2]  S. Glassman,et al.  Platelet Gel (AGF) Fails to Increase Fusion Rates in Instrumented Posterolateral Fusions , 2005, Spine.

[3]  R. Delamarter,et al.  Intervariability and Intravariability of Bone Morphogenetic Proteins in Commercially Available Demineralized Bone Matrix Products , 2006, Spine.

[4]  D. R. Sumner,et al.  Biologic Factors Affecting Spinal Fusion and Bone Regeneration , 1995, Spine.

[5]  M. Marone,et al.  Posterolateral intertransverse process spinal arthrodesis with rhBMP-2 in a nonhuman primate: important lessons learned regarding dose, carrier, and safety. , 1999, Journal of spinal disorders.

[6]  O. Kilian,et al.  Enhancement of bone formation in hydroxyapatite implants by rhBMP-2 coating. , 2008, Journal of biomedical materials research. Part B, Applied biomaterials.

[7]  Beth White.  Medical Devices and Combination Products , 2006 .

[8]  S. Boden,et al.  Biologic enhancement of spinal fusion. , 1995, Spine.

[9]  A. Domb,et al.  Poly(sebacic acid-co-ricinoleic acid) biodegradable carrier for paclitaxel--effect of additives. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[10]  M. Urist,et al.  Augmentation of spinal fusion with bone morphogenetic protein in dogs. , 1989, Clinical orthopaedics and related research.

[11]  C. Dickman,et al.  Anterior Lumbar Interbody Fusion Using rhBMP-2 With Tapered Interbody Cages , 2002, Journal of spinal disorders & techniques.

[12]  M. Boakye,et al.  Trends in pathological vertebral fractures in the United States: 1993 to 2004. , 2007, Journal of neurosurgery. Spine.

[13]  S. Lynch,et al.  Augment Bone Graft Products Compare Favorably With Autologous Bone Graft in an Ovine Model of Lumbar Interbody Spine Fusion , 2012, Spine.

[14]  J. Katz,et al.  Lumbar Spinal Fusions: Surgical Rates, Costs, and Complications , 1995, Spine.

[15]  Jeffrey C. Wang,et al.  Challenges to bone formation in spinal fusion. , 2011, Journal of biomechanics.

[16]  S. Boden,et al.  Use of Recombinant Human Bone Morphogenetic Protein-2 to Achieve Posterolateral Lumbar Spine Fusion in Humans: A Prospective, Randomized Clinical Pilot Trial 2002 Volvo Award in Clinical Studies , 2002, Spine.

[17]  N. Haas,et al.  Klinische Forschung im Verbund , 2010, Der Chirurg.

[18]  Charles L. Cooney,et al.  Lessons from innovation in drug-device combination products. , 2011, Advanced drug delivery reviews.

[19]  C. Branch,et al.  Posterior lumbar interbody fusion using recombinant human bone morphogenetic protein type 2 with cylindrical interbody cages. , 2004, The spine journal : official journal of the North American Spine Society.

[20]  G. J. Mattamal.  U.S. FDA Perspective on the Regulation of Cyanoacrylate Polymer Tissue Adhesives in Clinical Applications , 2007 .

[21]  F Layher,et al.  Osteointegration of hydroxyapatite-titanium implants coated with nonglycosylated recombinant human bone morphogenetic protein-2 (BMP-2) in aged sheep. , 2005, Bone.

[22]  G. Schmidmaier,et al.  Changing the Release Kinetics of Gentamicin from Poly(D, L-Lactide) Implant Coatings Using Only One Polymer , 2011, The International journal of artificial organs.

[23]  S. Bhang,et al.  Long-term delivery enhances in vivo osteogenic efficacy of bone morphogenetic protein-2 compared to short-term delivery. , 2008, Biochemical and biophysical research communications.

[24]  Yan Jin,et al.  Novel glycidyl methacrylated dextran (Dex-GMA)/gelatin hydrogel scaffolds containing microspheres loaded with bone morphogenetic proteins: formulation and characteristics. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[25]  John A. Jansen,et al.  Organic–Inorganic Surface Modifications for Titanium Implant Surfaces , 2008, Pharmaceutical Research.

[26]  S. Scheindlin.  Transdermal drug delivery: PAST, PRESENT, FUTURE. , 2004, Molecular interventions.

[27]  Jeffrey W. Smith,et al.  Fabrication of PLGA nanoparticles with a fluidic nanoprecipitation system , 2010, Journal of nanobiotechnology.

[28]  R. Milner,et al.  Bactericidal activity of antimicrobial coated polyurethane sleeves for external fixation pins , 2004, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[29]  N. Haas,et al.  [Clinical research in partnership: musculoskeletal surgery]. , 2010, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen.

[30]  W. Hutton,et al.  Experimental Spinal Fusion With Recombinant Human Bone Morphogenetic Protein‐2 , 1995, Spine.

[31]  R. Deyo,et al.  United States Trends in Lumbar Fusion Surgery for Degenerative Conditions , 2005, Spine.

[32]  S. Boden,et al.  The Efficacy of rhBMP-2 for Posterolateral Lumbar Fusion in Smokers , 2007, Spine.

[33]  G. Buttermann.  Prospective nonrandomized comparison of an allograft with bone morphogenic protein versus an iliac-crest autograft in anterior cervical discectomy and fusion. , 2008, The spine journal : official journal of the North American Spine Society.

[34]  Rui L. Reis,et al.  Incorporation of a sequential BMP-2/BMP-7 delivery system into chitosan-based scaffolds for bone tissue engineering. , 2009, Biomaterials.

[35]  Y. R. Rampersaud,et al.  Heterotopic Bone Formation With the Use of rhBMP2 in Posterior Minimal Access Interbody Fusion: A CT Analysis , 2007, Spine.

[36]  K. Leung,et al.  Periprosthetic Fractures: Epidemiology and Future Projections , 2011, Journal of orthopaedic trauma.

[37]  Cato T Laurencin,et al.  Polymers as biomaterials for tissue engineering and controlled drug delivery. , 2006, Advances in biochemical engineering/biotechnology.

[38]  Jong-Ho Lee,et al.  Enhanced bone regeneration with BMP-2 loaded functional nanoparticle-hydrogel complex. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[39]  Guangzhi Wang,et al.  Optimal delivery systems for bone morphogenetic proteins in orthopedic applications should model initial tissue repair structures by using a heparin-incorporated fibrin-fibronectin matrix. , 2008, Medical hypotheses.

[40]  N. P. Haas,et al.  Quantitative assessment of growth factors in reaming aspirate, iliac crest, and platelet preparation. , 2006, Bone.

[41]  S. Boden,et al.  Posterolateral Lumbar Intertransverse Process Spine Arthrodesis With Recombinant Human Bone Morphogenetic Protein 2/Hydroxyapatite‐Tricalcium Phosphate After Laminectomy in the Nonhuman Primate , 1999, Spine.

[42]  R. Reis,et al.  Materials in particulate form for tissue engineering. 2. Applications in bone , 2007, Journal of tissue engineering and regenerative medicine.

[43]  K. Chihara,et al.  Stimulatory effect of growth hormone on bone resorption and osteoclast differentiation. , 1996, Endocrinology.

[44]  K. Chihara,et al.  Stimulatory effect of bone morphogenetic protein‐2 on osteoclast‐like cell formation and bone‐resorbing activity , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[45]  E. Hunziker,et al.  The influence of BMP-2 and its mode of delivery on the osteoconductivity of implant surfaces during the early phase of osseointegration. , 2007, Biomaterials.

[46]  M. Markel,et al.  Cervical Interbody Fusion Cages: An Animal Model With and Without Bone Morphogenetic Protein , 1998, Spine.

[47]  K. Takaoka,et al.  Synthetic biodegradable polymers as drug delivery systems for bone morphogenetic proteins. , 2005, Advanced drug delivery reviews.

[48]  E. Hunziker,et al.  BMP-2 liberated from biomimetic implant coatings induces and sustains direct ossification in an ectopic rat model. , 2005, Bone.

[49]  P. Fratzl,et al.  Designing biomimetic scaffolds for bone regeneration: why aim for a copy of mature tissue properties if nature uses a different approach? , 2010 .

[50]  O. Eremin,et al.  The effects of smoking on fracture healing. , 2010, The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland.

[51]  Fotios Papadimitrakopoulos,et al.  PLGA/PVA hydrogel composites for long-term inflammation control following s.c. implantation. , 2010, International journal of pharmaceutics.

[52]  E. Argintar,et al.  Bone morphogenetic proteins in orthopaedic trauma surgery. , 2011, Injury.

[53]  D. Grainger,et al.  Demineralized bone matrix as a vehicle for delivering endogenous and exogenous therapeutics in bone repair. , 2012, Advanced drug delivery reviews.

[54]  David W Grainger,et al.  Drug/device combinations for local drug therapies and infection prophylaxis. , 2006, Biomaterials.

[55]  J. Burkus,et al.  Influence of rhBMP-2 on the Healing Patterns Associated With Allograft Interbody Constructs in Comparison With Autograft , 2006, Spine.

[56]  H. Seeherman,et al.  Locally delivered rhBMP‐2 enhances bone ingrowth and gap healing in a canine model , 2004, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[57]  J. Theis,et al.  Effects of bone morphogenetic protein-2 and hyaluronic acid on the osseointegration of hydroxyapatite-coated implants: an experimental study in sheep. , 2005, Journal of biomedical materials research. Part A.

[58]  V. Devescovi,et al.  Growth factors in bone repair , 2008, La Chirurgia degli organi di movimento.

[59]  N P Haas,et al.  Biodegradable poly(D,L-lactide) coating of implants for continuous release of growth factors. , 2001, Journal of biomedical materials research.

[60]  Robert Langer,et al.  Transdermal drug delivery , 2008, Nature Biotechnology.

[61]  M. Spector,et al.  Comparing ectopic bone growth induced by rhBMP‐2 on an absorbable collagen sponge in rat and rabbit models , 2006, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[62]  P. Giannoudis,et al.  Fracture healing: the diamond concept. , 2007, Injury.

[63]  K. Bulsara,et al.  Safety of transforaminal lumbar interbody fusion and intervertebral recombinant human bone morphogenetic protein-2. , 2005, Journal of neurosurgery. Spine.

[64]  Paula T Hammond,et al.  Tissue integration of growth factor-eluting layer-by-layer polyelectrolyte multilayer coated implants. , 2011, Biomaterials.

[65]  F K Kasper,et al.  Biodegradable composite scaffolds incorporating an intramedullary rod and delivering bone morphogenetic protein-2 for stabilization and bone regeneration in segmental long bone defects. , 2011, Acta biomaterialia.

[66]  T. Thillemann,et al.  Postoperative use of bisphosphonates and risk of revision after primary total hip arthroplasty: a nationwide population-based study. , 2010, Bone.

[67]  D. Wessinghage,et al.  LANGZEITERGEBNISSE NACH ZEMENTIERTEN HUFT-TOTALENDOPROTHESEN BEI CHRONISCHEN POLYARTHRITIDEN , 1998 .

[68]  N. Haas,et al.  Gentamicin coating of metallic implants reduces implant-related osteomyelitis in rats. , 2003, Bone.

[69]  M. Hu,et al.  Effect of chondroitin sulfate modification on rhBMP-2 release kinetics from collagen delivery system. , 2009, Journal of biomedical materials research. Part A.

[70]  J. Galante,et al.  Locally delivered rhTGF‐β2 enhances bone ingrowth and bone regeneration at local and remote sites of skeletal injury , 2001, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[71]  Gwo‐Jaw Wang,et al.  Controlled-release of rhBMP-2 carriers in the regeneration of osteonecrotic bone. , 2009, Biomaterials.

[72]  G Bergmann,et al.  Realistic loads for testing hip implants. , 2010, Bio-medical materials and engineering.

[73]  S. Allison.  Analysis of initial burst in PLGA microparticles , 2008 .

[74]  R. T. Allen,et al.  Bone Morphogenetic Protein-2 (BMP-2) in the Treatment of Pyogenic Vertebral Osteomyelitis , 2007, Spine.

[75]  E. Rodriguez-Merchan,et al.  The use of fibrin glue in surgery of the knee. , 2010, The Journal of bone and joint surgery. British volume.

[76]  D. Assimos,et al.  New generation tissue sealants and hemostatic agents: innovative urologic applications. , 2006, Reviews in urology.

[77]  Michael J Yaszemski,et al.  Retention of in vitro and in vivo BMP-2 bioactivities in sustained delivery vehicles for bone tissue engineering. , 2008, Biomaterials.

[78]  E. Hunziker,et al.  Delivery Mode and Efficacy of BMP-2 in Association with Implants , 2007, Journal of dental research.

[79]  Ian Harvey,et al.  Bone morphogenetic protein (BMP) for fracture healing in adults. , 2010, The Cochrane database of systematic reviews.

[80]  J M Toth,et al.  Experimental Spinal Fusion With Recombinant Human Bone Morphogenetic Protein-2 Without Decortication of Osseous Elements , 1997, Spine.

[81]  N. Haas,et al.  Local delivery of growth factors from coated titanium plates increases osteotomy healing in rats. , 2004, Bone.

[82]  Fotios Papadimitrakopoulos,et al.  Controlled release of dexamethasone from PLGA microspheres embedded within polyacid-containing PVA hydrogels , 2005, The AAPS Journal.

[83]  V K Goel,et al.  Epidemiology introduction. 1995 Focus Issue Meeting on Fusion. , 1995, Spine.

[84]  John K. Song,et al.  Recombinant Human Bone Morphogenetic Protein-2-Induced Radiculitis in Elective Minimally Invasive Transforaminal Lumbar Interbody Fusions: A Series Review , 2009, Spine.

[85]  N P Haas,et al.  Bone morphogenetic protein-2 coating of titanium implants increases biomechanical strength and accelerates bone remodeling in fracture treatment: a biomechanical and histological study in rats. , 2002, Bone.

[86]  James N Weinstein,et al.  United States’ Trends and Regional Variations in Lumbar Spine Surgery: 1992–2003 , 2006, Spine.

[87]  R. Delamarter,et al.  Graft Resorption With the Use of Bone Morphogenetic Protein: Lessons From Anterior Lumbar Interbody Fusion Using Femoral Ring Allografts and Recombinant Human Bone Morphogenetic Protein-2 , 2006, Spine.

[88]  I. Kron,et al.  A prospectus on tissue adhesives. , 2001, American journal of surgery.

[89]  D. Scharnweber,et al.  Effect of biological implant surface coatings on bone formation, applying collagen, proteoglycans, glycosaminoglycans and growth factors , 2008, Journal of materials science. Materials in medicine.

[90]  A. Riis,et al.  Risk factors for revision due to infection after primary total hip arthroplasty , 2010, Acta orthopaedica.

[91]  Byung-Soo Kim,et al.  Long-term and zero-order release of basic fibroblast growth factor from heparin-conjugated poly(L-lactide-co-glycolide) nanospheres and fibrin gel. , 2006, Biomaterials.

[92]  Joseph D. Smucker,et al.  Increased Swelling Complications Associated With Off-Label Usage of rhBMP-2 in the Anterior Cervical Spine , 2006, Spine.

[93]  Michael Y. Wang,et al.  A COMPREHENSIVE REVIEW OF THE SAFETY PROFILE OF BONE MORPHOGENETIC PROTEIN IN SPINE SURGERY , 2008, Neurosurgery.

[94]  G. J. Mattamal.  US FDA perspective on the regulations of medical-grade polymers: cyanoacrylate polymer medical device tissue adhesives , 2008, Expert review of medical devices.

[95]  S. Glassman,et al.  Adverse Effects Associated With High-Dose Recombinant Human Bone Morphogenetic Protein-2 Use in Anterior Cervical Spine Fusion , 2006, Spine.

[96]  M. Hilbe,et al.  Biodegradable sleeves for metal implants to prevent implant-associated infection: an experimental in vivo study in sheep. , 2012, Veterinary surgery : VS.

[97]  Yaron S Brin,et al.  Gentamicin extended release from an injectable polymeric implant. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[98]  C. Thompson,et al.  Tissue Adhesives: A Review , 2006 .

[99]  R. Vaidya,et al.  Complications of anterior cervical discectomy and fusion using recombinant human bone morphogenetic protein-2 , 2007, European Spine Journal.

[100]  A. M. Phillips.  Overview of the fracture healing cascade. , 2005, Injury.

[101]  S. Glassman,et al.  Clinical Outcomes and Fusion Success at 2 Years of Single-Level Instrumented Posterolateral Fusions With Recombinant Human Bone Morphogenetic Protein-2/Compression Resistant Matrix Versus Iliac Crest Bone Graft , 2006, Spine.

[102]  Daniel C. Lu,et al.  Corpectomy followed by the placement of instrumentation with titanium cages and recombinant human bone morphogenetic protein-2 for vertebral osteomyelitis. , 2007, Journal of neurosurgery. Spine.